Activation of distinct P2Y receptor subtypes stimulates insulin secretion in MIN6 mouse pancreatic β cells

Biochemical Pharmacology

Volumn 79, Issue 9, 2010, Pages 1317-1326

  Balasubramanian, Ramachandran ^a   de Azua, Inigo Ruiz ^a   Wess, Jürgen ^a   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

G protein coupled receptors; Nucleotides; Phospholipase C; Radioligand binding

Indexed keywords

2 CHLORO N6 METHYL N METHANOCARBA 2' DEOXYADENOSINE 3',5' BISPHOSPHATE; 2 IODO N6 METHYL N METHANOCARBA 2' DEOXYADENOSINE 3',5' BISPHOSPHATE; 2 METHYLTHIOADENOSINE 5' DIPHOSPHATE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 4 (2 IODO 6 METHYLAMINO 9H PURIN 9 YL) 2 PHOSPHONOOXYBICYCLO[3.1.0]HEXANE 1 METHANOL; CALCIUM; GLUCOSE; INSULIN; MESSENGER RNA; MRS 2211; MRS 2279; MRS 2365; N METHANOCARBA 2' DEOXY 2 METHYLTHIOADENOSINE 5' DIPHOSPHATE; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y13 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; PYRIDOXAL 5' PHOSPHATE 6 AZO(2 CHLORO 5 NITROPHENYL) 2,4 DISULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL DEATH; CELL MEMBRANE; CELL NUCLEUS; CELL PROTECTION; CELL STIMULATION; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FLOW CYTOMETRY; GENE EXPRESSION; INSULIN RELEASE; LIGAND BINDING; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; CALCIUM; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; INSULIN; INSULIN-SECRETING CELLS; MICE; MOLECULAR STRUCTURE; NUCLEOTIDES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77649190704     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.12.026     Document Type: Article

References (49)

1. Burnstock G., and Williams M. P2 purinergic receptors: modulation of cell function and therapeutic potential. J Pharmacol Exp Ther 295 (2000) 862-869
2. Burnstock G. Physiological and pathological roles of purines: an update. Drug Dev Res 28 (1998) 195-206
3. Ralevic V., and Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 50 (1998) 413-492
4. Abbracchio M.P., Saffrey M.J., Hopker V., and Burnstock G. Modulation of astroglial cell proliferation by analogues of adenosine and ATP in primary cultures of rat striatum. Neuroscience 59 (1994) 67-76
5. Van Kolen K., and Slegers H. Integration of P2Y receptor-activated signal transduction pathways in G protein-dependent signalling networks. Purinergic Signal 2 (2006) 451-469
6. Verspohl E.J., Johannwille B., Waheed A., and Neye H. Effect of purinergic agonists and antagonists on insulin secretion from INS-1 cells (insulinoma cell line) and rat pancreatic islets. Can J Physiol Pharmacol 80 (2002) 562-568
7. Bertrand G., Chapal J., Puech R., and Loubatieres-Mariani M.M. Adenosine-5′-O-(2-thiodiphosphate) is a potent agonist at P2 purinoceptors mediating insulin secretion from perfused rat pancreas. Br J Pharmacol 102 (1991) 627-630
8. Fernandez-Alvarez J., Hillaire-Buys D., Loubatieres-Mariani M.M., Gomis R., and Petit P. P2 receptor agonists stimulate insulin release from human pancreatic islets. Pancreas 22 (2001) 69-71
9. Hauge-Evans A.C., Squires P.E., Belin V.D., Roderigo-Milne H., Ramracheya R.D., Persaud S.J., et al. Role of adenine nucleotides in insulin secretion from MIN6 pseudoislets. Mol Cell Endocrinol 191 (2002) 167-176
10. Poulsen C.R., Bokvist K., Olsen H.L., Hoy M., Capito K., Gilon P., et al. Multiple sites of purinergic control of insulin secretion in mouse pancreatic β-cells. Diabetes 48 (1999) 2171-2181
11. Farret A., Vignaud M., Dietz S., Vignon J., Petit P., and Gross R. P2Y purinergic potentiation of glucose-induced insulin secretion and pancreatic β-cell metabolism. Diabetes 53 (2004) S63-S66
12. 6 receptors. Biochem Biophys Res Commun 370 (2008) 499-503
13. Lee D.H., Park K.S., Kim D.R., Lee J.W., and Kong I.D. Dual effect of ATP on glucose-induced insulin secretion in HIT-T15 cells. Pancreas 37 (2008) 302-308
14. von Kügelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110 (2006) 415-432
15. 1 receptor of human platelets. J Thromb Haemost 4 (2006) 861-868
16. 13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther 311 (2004) 1038-1043
17. 6 receptor agonists. Bioorg Med Chem 16 (2008) 6319-6332
18. Pendergast W., Yerxa B.R., Douglass J.G., Shaver S.R., Dougherty R.W., Redick C.C., et al. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5′-polyphosphates. Bioorg Med Chem Lett 11 (2001) 157-160
19. 6 nucleotide receptors. Biochem Pharmacol 67 (2004) 1763-1770
20. 1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther 316 (2006) 556-563
21. 1 receptors. Br J Pharmacol 147 (2006) 459-467
22. 125I]MRS2500); in preparation.
23. 6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosis. Cell Mol Neurobiol 23 (2003) 401-418
24. 6, but not P2Y4 nucleotide receptors. Biochem Pharmacol 65 (2003) 923-931
25. Miyazaki J., Araki K., Yamato E., Ikegami H., Asano T., Shibasaki Y., et al. Establishment of a pancreatic β cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127 (1990) 126-132
26. 6-like receptor in arteries. Mol Pharmacol 62 (2002) 1438-1445
27. 1 receptor with a high affinity radiolabeled antagonist. Mol Pharmacol 62 (2002) 1249-1257
28. Hoorens A., Van de Casteele M., Klöppel G., and Pipeleers D. Glucose promotes survival of rat pancreatic β cells by activating synthesis of proteins which suppress a constitutive apoptotic program. J Clin Invest 98 (1996) 1568-1574
29. Kimoto K., Suzuki K., Kizaki T., Hitomi Y., Ishida H., and Katsuta H. Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 303 (2003) 112-119
30. Yasuda J., Nishioka W., Sakudo A., Yama S., Setoguchi R., Saeki K., et al. Suppressor mechanism of serum thymic factor on tumor necrosis factor-α-induced apoptosis in the mouse pancreatic β-cell line. Biophys Biochem Res Commun 311 (2003) 501-505
31. Riccardi C., and Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protocols 1 (2006) 1458-1461
32. Choi S.E., Choi K.M., Yoon I.H., Shin J.Y., Kim J.S., Park W.Y., et al. IL-6 protects pancreatic islet β cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl Immunol 13 (2004) 43-53
33. 2+ mobilization and insulin secretion in mouse pancreatic islets. Purinergic Signal 4 (2008) 365-375
34. Jacobson K.A., Ivanov A.A., de Castro S., Harden T.K., and Ko H. Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal 5 (2009) 75-89
35. 1 receptor antagonists. J Med Chem 46 (2003) 4974-4987
36. 1 receptor antagonist. Br J Pharmacol 135 (2002) 2004-2010
37. 6-methyl-2′-deoxyadenosine-3-,5-bisphosphate. Br J Pharmacol 124 (1998) 1-3
38. Petit P., Lajoix A.D., and Gross R. P2 purinergic signalling in the pancreatic β-cell: control of insulin secretion and pharmacology. Eur J Pharm Sci 37 (2009) 67-75
39. Winzell M.S., and Ahrén B. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacol Ther 116 (2007) 437-448
40. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 8 (2009) 369-385
41. Petit P., Hillaire-Buys D., Manteghetti M., Debrus S., Chapal J., and Loubatières-Mariani M.M. Evidence for two different types of P2 receptors stimulating insulin secretion from pancreatic B cell. Br J Pharmacol 125 (1998) 1368-1374
42. Farret A., Filhol R., Linck N., Manteghetti M., Vignon J., Gross R., et al. P2Y receptor mediated modulation of insulin release by a novel generation of 2-substituted-5′-O-(1-boranotriphosphate)-adenosine analogues. Pharm Res 23 (2006) 2665-2671
43. Hutchinson D.S., Summers R.J., and Bengtsson T. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacol Ther 119 (2008) 291-310
44. Chevassus H., Roig A., Belloc C., Lajoix A.D., Broca C., Manteghetti M., et al. P2Y receptor activation enhances insulin release from pancreatic beta-cells by triggering the cyclic AMP/protein kinase A pathway. Naunyn Schmiedebergs Arch Pharmacol 366 (2002) 464-469
45. 2+ stores and arachidonic acid metabolism. J Clin Invest 101 (1998) 1623-1632
46. Donath M.Y., Schumann D.M., Faulenbach M., Ellingsgaard H., Perren A., and Ehses J.A. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31 (2008) S161-S164
47. Chen J., Saxena G., Mungrue I.N., Lusis A.J., and Shalev A. Thioredoxin-interacting protein: a critical link between glucose toxicity and β-cell apoptosis. Diabetes 57 (2008) 938-944
48. 6 receptor activation. Pharmacol Res 58 (2008) 232-239
49. 6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. J Biol Chem 280 (2005) 16909-16915